Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPRA: Empagliflozin Effects on RAS in CKD
NCT03078101Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in chronic kidney disease (CKD), sponsored by Medical University of Vienna. Started Apr 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03078101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078101.